Staining with lissamine green: a guide to dry eye

Article

Degree and pattern of staining with lissamine green is a good objective indicator of the severity of tear deficiency, according to a report published in the July issue of Eye and Contact Lens.

Degree and pattern of staining with lissamine green is a good objective indicator of the severity of tear deficiency, according to a report published in the July issue of Eye and Contact Lens.

James McCulley and colleagues from the University of Texas Southwestern Medical Center, USA found that the severity of dry eye correlates with the location of stain patterns. They examined the stain patterns in 22 patients with varying degrees of dry eye and in 11 patients with ocular disease who served as controls.

The researchers found that stains limited to the whites of the eyes between the lids toward the nose do not necessarily indicate dry eye but could be caused by environmental factors such as pollution. Stains that appear in the whites of the eye towards the ear are often symptomatic of dry eye. Finally, stains that appear on the cornea indicate a break in surface cells which can lead to serious bacterial infections.

The team suggested that these guidelines may allow for earlier diagnosis, allowing clinicians to offer more treatment options and preventing disease progression.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.